Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer
Interventions: DRUG: ertumaxomab
Sponsor: Neovii Biotech